Related Experiment Video
Updated: Jul 1, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Cure in Myasthenia Gravis: An Unmet Need
Shadi El-Wahsh1,2, Fiona Chan1,2, Stephen Reddel1,2
1Concord Repatriation General Hospital, Concord, New South Wales, Australia.
Muscle & Nerve
|June 30, 2026
Summary
A cure for myasthenia gravis (MG) is needed. Current treatments manage symptoms but are chronic, risky, and often ineffective, highlighting the unmet need for a true MG cure.
Area of Science:
- Neurology
- Immunology
- Medical Research
Background:
- Myasthenia gravis (MG) treatments currently focus on symptom reduction and broad immune suppression.
- These treatments require chronic administration, carry significant risks, and often result in incomplete remission or potential disability.
- Treatment-free remission is infrequent, underscoring the need for a definitive cure.
Purpose of the Study:
- To define the criteria for a cure for myasthenia gravis.
- To evaluate current and emerging therapeutic strategies against these criteria.
- To identify the unmet need for a cure in myasthenia gravis.
Main Methods:
- Literature review and analysis of existing MG treatment paradigms.
- Evaluation of thymectomy outcomes, including MGTX trial data.
- Assessment of novel therapeutic approaches, including cellular therapies and antigen-specific treatments.
Main Results:
- A cure is defined as complete, treatment-free remission with high success probability, low relapse risk, repeatable treatment options, minimal toxicity, and cost-effectiveness.
- Thymectomy offers a potential cure for a subset of ACHR+ MG patients, with a 52% steroid-free remission rate in MGTX trial analysis.
- Emerging therapies, while effective, are largely chronic suppressive strategies with significant costs and potential toxicities.
Conclusions:
- Myasthenia gravis currently lacks a universally effective cure.
- Existing treatments fall short of the defined cure criteria due to chronicity, risks, and incomplete efficacy.
- Further research into antigen-specific and potentially curative therapies is essential to address the unmet need for a myasthenia gravis cure.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...